About: Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma
Creator	Takahashi, Hiroki Uchida, Hiroaki Hasegawa, Tadashi Hirai, Sachie Nishii, Yukari Sakuma, Yuji Sumi, Toshiyuki Tada, Makoto Tanaka, Yusuke Watanabe, Atsushi Yamada, Gen Yamaguchi, Miki
Source	Elsevier; Medline; PMC
abstract	Abstract EGFR-mutant lung adenocarcinomas contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and can grow independently of EGFR. To kill these cancer cells, we need a novel therapeutic approach other than EGFR inhibitors. If a molecule is specifically expressed on the cell surface of such EGFR-independent EGFR-mutant cancer cells, it can be a therapeutic target. We found that a mesenchymal EGFR-independent subline derived from HCC827 cells, an EGFR-mutant lung adenocarcinoma cell line, expressed angiotensin-converting enzyme 2 (ACE2) to a greater extent than its parental cells. ACE2 was also expressed at least partially in most of the primary EGFR-mutant lung adenocarcinomas examined, and the ACE2 expression level in the cancer cells was much higher than that in normal lung epithelial cells. In addition, we developed an anti-ACE2 mouse monoclonal antibody (mAb), termed H8R64, that was internalized by ACE2-expressing cells. If an antibody-drug conjugate consisting of a humanized mAb based on H8R64 and a potent anticancer drug were produced, it could be effective for the treatment of EGFR-mutant lung adenocarcinomas.
has issue date	2017-06-03(xsd:dateTime)
bibo:doi	10.1016/j.bbrc.2017.04.102
bibo:pmid	28433633
has license	els-covid
sha1sum (hex)	3d4106215f4d9cc9189f90d1beac917bdf3d9b09
schema:url	https://doi.org/10.1016/j.bbrc.2017.04.102
resource representing a document's title	Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma
has PubMed Central identifier	PMC7092918
has PubMed identifier	28433633
schema:publication	Biochemical and Biophysical Research Communications
resource representing a document's body	covid:3d4106215f4d9cc9189f90d1beac917bdf3d9b09#body_text
is schema:about of	named entity 'MUTANT' named entity 'expressed' named entity 'EGFR inhibitors' named entity 'target' named entity 'lung adenocarcinoma' named entity 'CONJUGATE' named entity 'APPROACH' named entity 'THERAPEUTIC TARGET' named entity 'MOLECULE' named entity 'THESE' named entity 'MUCH' named entity 'EGFR INHIBITORS' named entity 'ITS' named entity 'CELLS' named entity 'MAB' covid:arg/3d4106215f4d9cc9189f90d1beac917bdf3d9b09 named entity 'HIGHER' named entity 'MUTANT' named entity 'POTENTIAL' named entity 'EPITHELIAL CELLS' named entity 'HCC827' named entity 'PRIMARY' named entity 'PARENTAL' named entity 'ACE2' named entity 'HAVE' named entity 'IS A' named entity 'THERAPEUTIC TARGET' named entity 'LUNG ADENOCARCINOMA' named entity 'TRANSITION' named entity 'COULD BE' named entity 'EFFECTIVE' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'FOUND' named entity 'PARTIALLY' named entity 'EGFR' named entity 'GREATER' named entity 'EPITHELIAL' named entity 'EXPRESSED' named entity 'CONTAIN' named entity 'CANCER CELLS' named entity 'HUMANIZED' named entity 'EGFR' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'BASED' named entity 'GROW' named entity 'S T' named entity 'ANTIBODY' named entity 'EXPRESSION LEVEL' named entity 'THERAPEUTIC' named entity 'LUNG ADENOCARCINOMA CELL LINE' named entity 'ADDITION' named entity 'EXAMINED' named entity 'TREATMENT' named entity 'INDEPENDENT' named entity 'NEED' named entity 'DRUG' named entity 'KILL' named entity 'MOUSE MONOCLONAL ANTIBODY' named entity 'DERIVED' named entity 'CELL SURFACE' named entity 'OTHER THAN' named entity 'EXTENT' named entity 'NOVEL' named entity 'SUBPOPULATION' named entity 'MESENCHYMAL' named entity 'ADENOCARCINOMAS' named entity 'LUNG' named entity 'MOST OF' named entity 'kill' named entity 'mAb'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software